Cumberland Pharmaceuticals (CPIX) EBITDA Margin Growth (3y) (2013 - 2026)
Powered by 
Analysis
Cumberland Pharmaceuticals (CPIX) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn | 120.00 |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn | 531.00 |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn | 3,082.00 |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn | 842.00 |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 214.00 |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn | -963.00 |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 2,139.00 |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn | -1,031.00 |
| 10 | Cumberland Pharmaceuticals | 96.11 Mn | 92.24 Mn | - | -189,886.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -189,886.00 |
| Mar 31, 2026 | -1,767.00 |
| Dec 31, 2025 | 1,494.00 |
| Sep 30, 2025 | -2,117.00 |
| Jun 30, 2025 | -80,128.00 |
| Mar 31, 2025 | 2,259.00 |
| Dec 31, 2024 | 3,468.00 |
| Sep 30, 2024 | 72.00 |
| Jun 30, 2024 | 543.00 |
| Mar 31, 2024 | -1,892.00 |
| Dec 31, 2023 | -4,905.00 |
| Sep 30, 2023 | -544.00 |
| Jun 30, 2023 | 1,668.00 |
| Mar 31, 2023 | 555.00 |
| Dec 31, 2022 | 1,151.00 |
| Sep 30, 2022 | 4,356.00 |
| Jun 30, 2022 | -335.00 |
| Mar 31, 2022 | 360.00 |
| Dec 31, 2021 | -3,557.00 |
| Sep 30, 2021 | 191.00 |